Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Jubilant Pharmova Ltd (JUBLPHARMA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530019 NSE: JUBLPHARMA Pharmaceuticals & Drugs | Small Cap | Jubilant Pharmova Share Price
₹930.85 -3.95 (-0.42%)
As on 03-Aug'26 16:59
Jubilant Pharmova Ltd (JUBLPHARMA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530019 NSE: JUBLPHARMA Pharmaceuticals & Drugs | Small Cap | Jubilant Pharmova Share Price
₹930.85 -3.95 (-0.42%)
As on 03-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹14,827 Cr.
Current Price
₹930.9
52-Week Low / High
₹784 / 1,184
TTM EPS
₹1.3
TTM Sales
₹264 Cr.
Book Value per Share
₹145.2
P/E Ratio
745.06
Higher than its 5-year historical median
Industry PE
54.3
Price to Book (P/B)
6.41
Higher than its 5-year historical median
Price to Sales (P/S)
56.27
Higher than its 5-year historical median
EV/EBITDA
290.36
Higher than its 5-year historical median
Dividend Yield
0.54%
Profitability Efficiency
Return on Equity (ROE)
0.87%
Underperforms industry median
Return on Capital Employed (ROCE)
1.46%
Underperforms industry median
Return on Assets (ROA)
0.75%
Operating Profit Margin
17.6%
Net Profit Margin
7.55%
Gross Profit Margin
16.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-70.51%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
19.9%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
-10.36%
Asset Quality
Promoter Holding
47.68%
Pledged shares (%) of Promoter's holding (%)
6.58%
Reserves
₹2,296 Cr.
Equity
₹15.9 Cr.
Face Value
₹1
All Time Low / High
₹3.51 / 1309.00
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Jubilant Pharmova Ltd a good quality company?
Jubilant Pharmova Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Jubilant Pharmova Ltd performance compare with that of its Peers?
Revenue growth of Jubilant Pharmova Ltd vs industry peers?
Jubilant Pharmova Ltd revenue CAGR is -24.99%, compared to the industry median CAGR of 5.55%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Jubilant Pharmova Ltd?
Promoters hold 47.68% of the Jubilant Pharmova Ltd, with 6.58% of their stake pledged, indicating low pledge risk.
Stock return of Jubilant Pharmova Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 11.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jubilant Pharmova Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 7.1% | 7.6% | 13.6% | 8.1% | 10.1% | 11.8% | 4.4% | 3.7% | 2.6% | 2% | - |
| Value Creation Index ⓘ | -0.5 | -0.4 | 0.0 | -0.4 | -0.3 | -0.1 | -0.7 | -0.7 | -0.8 | -0.9 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 2,656 | 2,491 | 3,306 | 3,439 | 3,140 | 2,710 | 726 | 810 | 785 | 231 | 264 |
| Sales YoY Gr. | - | -6.2% | 32.7% | 4% | -8.7% | -13.7% | -73.2% | 11.6% | -3.1% | -70.5% | - |
| Adj EPS ⓘ | 4.8 | 4.8 | 16.1 | 10.3 | 20.6 | 13.5 | 5.1 | 3.1 | 2 | 1.4 | 1.3 |
| YoY Gr. | - | 0.2% | 234.6% | -35.7% | 99.4% | -34.6% | -62% | -39.8% | -33.8% | -31.9% | - |
| BVPS (₹) ⓘ | 126.3 | 128.2 | 141.2 | 146.9 | 163.7 | 80.5 | 153.1 | 151.6 | 148.6 | 145 | 145.2 |
| Adj Net Profit ⓘ | 76.4 | 76.4 | 256 | 165 | 328 | 215 | 81.6 | 49.1 | 32.5 | 22.2 | 20 |
| Cash Flow from Ops. ⓘ | 164 | 419 | 558 | 182 | 317 | 608 | -3.6 | -65.1 | 143 | 136 | - |
| Debt/CF from Ops. ⓘ | 11 | 4.1 | 2.6 | 9.4 | 6.2 | 0.8 | -49 | -4.6 | 2.4 | 2.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -23.8% | -40.6% | -31.7% | -70.5% | ||||
| Adj EPS ⓘ | -12.8% | -41.7% | -35.3% | -31.9% | ||||
| BVPSⓘ | 1.6% | -2.4% | -1.8% | -2.4% | ||||
| Share Price | 11.2% | 7% | 35.4% | -18.9% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 3.9 | 3.8 | 11.9 | 7.2 | 13.3 | 11 | 4.4 | 2 | 1.4 | 1 | 0.9 |
| Op. Profit Mgn % ⓘ | 11.9 | 13 | 16.4 | 10 | 12.1 | 15.8 | 1.1 | 0.4 | 2.3 | 17.6 | 18.5 |
| Net Profit Mgn % ⓘ | 2.9 | 3.1 | 7.7 | 4.8 | 10.5 | 7.9 | 11.2 | 6.1 | 4.1 | 9.6 | 7.6 |
| Debt to Equity ⓘ | 0.9 | 0.8 | 0.6 | 0.7 | 0.8 | 0.4 | 0.1 | 0.1 | 0.2 | 0.1 | 0 |
| Working Cap Days ⓘ | 195 | 154 | 133 | 139 | 161 | 102 | 139 | 250 | 262 | 827 | 35 |
| Cash Conv. Cycle ⓘ | 40 | 44 | 23 | 28 | 41 | 24 | 67 | 136 | 142 | 326 | -5 |
Valuation of Jubilant Pharmova - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.40 | 5.40 | 5.40 | 6.58 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,491 | 3,306 | 3,439 | 3,140 | 2,709 | 726 | 810 | 785 | 231 | 264 |
| Operating Expenses ⓘ + | 2,173 | 2,767 | 3,118 | 2,769 | 2,282 | 719 | 807 | 768 | 191 | 215 |
| Operating Profit ⓘ | 318 | 539 | 321 | 371 | 427 | 6 | 3 | 17 | 41 | 49 |
| Operating Profit Margin (%) | 12.8% | 16.3% | 9.3% | 11.8% | 15.8% | 0.9% | 0.4% | 2.1% | 17.6% | 18.5% |
| Other Income ⓘ + | 52 | 46 | 78 | 173 | 48 | 126 | 138 | 103 | 20 | 2 |
| Interest ⓘ | 174 | 135 | 129 | 136 | 102 | 11 | 19 | 30 | 13 | 7 |
| Depreciation ⓘ | 81 | 83 | 86 | 107 | 100 | 37 | 43 | 48 | 7 | 6 |
| Profit Before Tax ⓘ | 115 | 368 | 183 | 299 | 273 | 85 | 79 | 42 | 41 | 29 |
| Tax ⓘ | 35 | 104 | 36 | -22 | 59 | 4 | 29 | 10 | 19 | 9 |
| Profit After Tax | 79 | 263 | 148 | 321 | 214 | 80 | 50 | 32 | 22 | 20 |
| PAT Margin (%) | 3.2% | 8.0% | 4.3% | 10.2% | 7.9% | 11.1% | 6.2% | 4.0% | 9.6% | 7.6% |
| Adjusted EPS (₹) | 5.0 | 16.5 | 9.3 | 20.2 | 13.5 | 5.1 | 3.1 | 2.0 | 1.4 | 1.3 |
| Dividend Payout Ratio (%) | 60.30% | 18.10% | 48.60% | 24.80% | 37.10% | 98.90% | 159.30% | 251.60% | 358.10% | 399.50% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 2,042 | 2,249 | 2,340 | 2,607 | 1,282 | 2,439 | 2,411 | 2,362 | 2,305 | 2,294 | |
| Debt + | 1,564 | 1,250 | 1,602 | 1,951 | 493 | 174 | 302 | 340 | 292 | 50 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 487 | 749 | 596 | 619 | 16 | 159 | 164 | 148 | 155 | 9 | |
| Others Liabilities ⓘ | 288 | 376 | 325 | 257 | 53 | 89 | 115 | 129 | 146 | 35 | |
| Total Liabilities ⓘ | 4,382 | 4,625 | 4,864 | 5,433 | 1,845 | 2,860 | 2,991 | 2,980 | 2,898 | 2,387 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 1,421 | 1,438 | 1,491 | 1,865 | 127 | 637 | 687 | 711 | 699 | 116 | |
| CWIP ⓘ | 65 | 115 | 284 | 59 | 0 | 35 | 47 | 37 | 19 | 12 | |
| Investments ⓘ | 1,710 | 1,706 | 1,764 | 1,764 | 1,646 | 1,646 | 1,657 | 1,657 | 1,657 | 2,176 | |
| Inventories | 454 | 586 | 492 | 656 | 0 | 323 | 314 | 251 | 232 | 0 | |
| Trade Receivables | 386 | 494 | 481 | 425 | 0 | 131 | 189 | 194 | 206 | 24 | |
| Cash Equivalents | 77 | 38 | 35 | 258 | 40 | 23 | 11 | 36 | 13 | 10 | |
| Others Assets ⓘ | 269 | 248 | 317 | 406 | 31 | 66 | 87 | 94 | 72 | 50 | |
| Total Assets ⓘ | 4,382 | 4,625 | 4,864 | 5,433 | 1,845 | 2,860 | 2,991 | 2,980 | 2,898 | 2,387 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 419 | 558 | 182 | 317 | 608 | -4 | -65 | 143 | 136 | 94 |
| Cash Flow From Investing Activity ⓘ + | -43 | -127 | -285 | -198 | 178 | 93 | 31 | -40 | -2 | 44 |
| Cash Flow From Financing Activity ⓘ + | -338 | -470 | 85 | -41 | -782 | -107 | 23 | -78 | -157 | -130 |
| Net Cash Flow ⓘ | 38 | -40 | -18 | 78 | 5 | -18 | -12 | 25 | -24 | 7 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 3.9 | 12.28 | 6.43 | 12.98 | 11.03 | 4.33 | 2.06 | 1.32 | 0.95 | 0.87 |
| ROCE (%) | 7.64 | 13.57 | 8.1 | 10.1 | 11.82 | 4.36 | 3.67 | 2.64 | 2.03 | 1.46 |
| Asset Turnover Ratio | 0.6 | 0.74 | 0.72 | 0.61 | 0.74 | 0.31 | 0.28 | 0.26 | 0.08 | 0.1 |
| PAT to CFO Conversion(x) | 5.3 | 2.12 | 1.23 | 0.99 | 2.84 | -0.05 | -1.3 | 4.47 | 6.18 | 4.7 |
| Working Capital Days | ||||||||||
| Receivable Days | 50.60 | 48 | 51.70 | 52.70 | 0 | 65.70 | 71.90 | 89 | 315.90 | 159.40 |
| Inventory Days | 64.70 | 56.80 | 57.20 | 66.70 | 0 | 162.50 | 143.50 | 131.30 | 381.20 | 0 |
| Payable Days | 118.60 | 127.40 | 119.60 | 131.60 | 79.80 | 95.80 | 142.10 | 160.50 | 0 | 0 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Jubilant Pharmova Ltd FAQs
The current trading price of Jubilant Pharmova on 03-Aug-2026 16:59 is ₹930.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Aug-2026 the market cap of Jubilant Pharmova stood at ₹14,826.7 Cr
The latest P/E ratio of Jubilant Pharmova as of 02-Aug-2026 is 745.1.
The latest P/B ratio of Jubilant Pharmova as of 02-Aug-2026 is 6.41.
The 52-week high of Jubilant Pharmova is ₹1,183.9 and the 52-week low is ₹783.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jubilant Pharmova is ₹264 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Jubilant Pharmova Ltd is a average quality company.
The key valuation ratios of Jubilant Pharmova Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Jubilant Pharmova Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Jubilant Pharmova Ltd
Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.
The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.
The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.
Business area of the company
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.
Business segments
- Pharmaceuticals
- Life Science Ingredients
- Drug Discovery & Development Solutions
- India Branded Pharmaceuticals
Awards
2012
- NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility. National Quality Excellence Award for best in Class manufacturing presented by Stars of the Industry Group.CII ‘National Award for Excellence in Water Management 2012’ as ‘Water Efficient Unit’ for Gajraula Unit.
- Economic Times - Frost & Sullivan India Manufacturing Excellence Gold Award - Process Sector for 2012. I.C.C. Award for Water Resource Management in Chemical Industry for the year 2011.
2013
- Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau.
- Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013.
- Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’.
2014
- Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014.
- BRI Partners with Jubilant Life Sciences to Bring XylamaxTM to the South Asia Poultry Market.
- Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014.
- Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area.
- IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery.
- Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014.
- Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutical.
2015
- Jubilant Life Sciences conferred with Golden Peacock National Quality Award.
- Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15.
2016
- Sustainability Award for Best Green Process in ‘Chemical Sector’ by ‘FICCI Chemicals & Petrochemicals Awards, 2016’.
- Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12.
- 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under ‘Chemicals and Pharmaceutical sector’ - Gajraula plant, India.
2017
- Social Entrepreneur of the Year (SEOY)-India Award 2017.
- Finalists for Social Entrepreneur of the Year (SEOY) India 2017 Award.
- ‘Second Awards’ under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
